Premium
COST‐EFFICIENCY OF A LONG‐ACTING CEPHALOSPORIN AGENT
Author(s) -
Hall J. C.,
Mander J.,
Christiansen K.,
Reid C.,
Cooney M.,
Gibb S. M.
Publication year - 1988
Publication title -
australian and new zealand journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.111
H-Index - 51
eISSN - 1445-2197
pISSN - 0004-8682
DOI - 10.1111/j.1445-2197.1988.tb01105.x
Subject(s) - medicine , cephalosporin , ceftriaxone , third generation , surgery , antibiotics , microbiology and biotechnology , telecommunications , computer science , biology
In a prospective longitudinal study of patients in a general surgical ward, the relative cost‐efficiencies of a long‐acting third generation cephalosporin (ceftriaxone—mean plasma elimination t 1/2 390 min) and a short‐acting second generation cephalosporin (cephamandole: mean plasma elimination t 1/2 32 min) were determined. The total cost of therapy for 24 h was $32.88 for cephamandole and $22.78 for ceftriaxone, that is, a reduction of 31%. Considerable cost containment can be achieved by using third generation cephalosporin agents that only require the administration of one intravenous injection per day.